Compare Ascendis Pharma A/S (ASND) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs JPMorgan Chase & Co — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while JPMorgan Chase & Co trades at $337.87 (market cap $901.58B). The key difference: JPMorgan Chase & Co is far larger — about 50.8× Ascendis Pharma A/S's market cap, and JPMorgan Chase & Co pays a 1.78% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | JPM | |
|---|---|---|
Market Cap | $17.74B | $901.58B |
Sector | Health | Financials |
52-Week High | $277.18 | $339.22 |
52-Week Low | $163.32 | $282.84 |
Enterprise Value | $18.11B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
JPMorgan Chase (JPM) trades at $336.47, up 0.3% with a bullish technical signal. The stock shows strong fundamentals with $181.85B revenue and 31.61% net margin in 2025, though Q4 2025 EPS missed expectations. Analyst consensus is Moderate Buy with a $360.38 price target, representing 7% upside. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 2026 earnings on April 14.
JPM offers solid investment potential with strong ROE (17.03%) and consistent earnings beats, but faces risks from geopolitical tensions and cybersecurity threats. The current valuation at 16.11 P/E appears reasonable given the bank's market leadership position. Investors should monitor Q2 2026 earnings results for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
